Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial
Author:
Publisher
Wiley
Subject
Hepatology
Reference27 articles.
1. NASH: Clinical assessment of 827 patients from two separate academic medical centers with validation of a clinical scoring system for advanced hepatic fibrosis;Harrison;Gut,2008
2. Nonalcoholic fatty liver disease;Angulo;N Engl J Med,2002
3. Benefits of lifestyle modification in NAFLD;Harrison;Gut,2007
4. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients;Harrison;Aliment Pharmacol Ther,2004
5. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease;Zelber-Sagi;Clin Gastroenterol Hepatol,2006
Cited by 390 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes;Diabetology & Metabolic Syndrome;2024-01-19
2. The effect of orlistat in the treatment of non-alcoholic fatty liver in adolescents with overweight and obese;European Journal of Pediatrics;2023-12-11
3. Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease;Livers;2023-11-23
4. Advancements in Understanding and Treating NAFLD: A Comprehensive Review of Metabolic-Associated Fatty Liver Disease and Emerging Therapies;Livers;2023-11-07
5. Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD);Livers;2023-10-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3